Clinical aspects of Monoclonal B-cell lymphocytosis

Cancer Control

Volumn 19, Issue 1, 2012, Pages 8-17

  Mowery, Yvonne M ^a   Lanasa, Mark C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FAMILIAL CANCER; HEPATITIS C VIRUS; HEREDITY; HUMAN; LEUKEMIA; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALIGNANT TRANSFORMATION; MONOCLONAL B LYMPHOCYTE LYMPHOCYTOSIS; PATHOGENESIS; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 83255164820     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900102     Document Type: Review

References (71)

1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
2. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100(2):635-639.
3. Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6): 575-583.
4. Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009;27(24):3959-3963.
5. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed May 20, 2011.
6. Shim YK, Middleton DC, Caporaso NE, et al. Prevalence of monoclonal B-cell lymphocytosis: a systematic review. Cytometry B Clin Cytom. 2010;78(suppl 1):S10-S18.
7. Dagklis A, Fazi C, Sala C, et al. The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. Blood. 2009;114(1):26-32.
8. Ghia P, Prato G, Scielzo C, et al. Monoclonal CD5+ and CD5- Blymphocyte expansions are frequent in the peripheral blood of the elderly. Blood. 2004;103(6):2337-2342.
9. Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009;114(1):33-37.
10. Shim YK, Vogt RF, Middleton D, et al. Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population. Cytometry B Clin Cytom. 2007;72(5):344-353.
11. Rachel JM, Zucker ML, Fox CM, et al. Monoclonal B-cell lymphocytosis in blood donors. Br J Haematol. 2007;139(5):832-836.
12. Matos DM, Ismael SJ, Scrideli CA, et al. Monoclonal B-cell lymphocytosis in first-degree relatives of patients with sporadic (non-familial) chronic lymphocytic leukaemia. Br J Haematol. 2009;147(3):339-346.
13. Marti GE, Carter P, Abbasi F, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2003;52(1):1-12.
14. Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100(7):2289-2290.
15. Goldin LR, Lanasa MC, Slager SL, et al. Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol. 2010;151(2):152-158.
16. Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005;130(3):325-332.
17. Ghia P, Fazi C, Pecciarini L, et al. CLL-like MBL in the general population persist over time, without clinical progression, though carrying the same cytogenetic abnormalities of CLL. Presented at the 52nd ASH Annual Meeting and Exposition. December 4-7,2010, Orlando, FL. Blood (ASH Meeting Abstracts). 2010;116(21):2440. Abstract.
18. Shanafelt TD, Ghia P, Lanasa MC, et al. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. Leukemia. 2010;24(3):512-520.
19. de Tute R, Yuille M, Catovsky D, et al. Monoclonal B-cell lymphocytosis (MBL) in CLL families: substantial increase in relative risk for young adults. Leukemia. 2006;20(4):728-729.
20. Del Giudice I, Mauro FR, De Propris MS, et al. Identification of monoclonal B-cell lymphocytosis among sibling transplant donors for chronic lymphocytic leukemia patients. Blood. 2009;114(13):2848-2849.
21. Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet. 2010;42(2):132-136.
22. Slager SL, Goldin LR, Strom SS, et al. Genetic susceptibility variants for chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1098-1102.
23. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome- wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2008;40(10):1204-1210.
24. Crowther-Swanepoel D, Corre T, Lloyd A, et al. Inherited genetic susceptibility to monoclonal B-cell lymphocytosis. Blood. 2010;116(26):5957-5960.
25. Ishibe N, Sgambati MT, Fontaine L, et al. Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry. Leuk Lymphoma. 2001;42(1-2):99-108.
26. Wiernik PH, Ashwin M, Hu XP, et al. Anticipation in familial chronic lymphocytic leukaemia. Br J Haematol. 2001;113(2):407-414.
27. Mauro FR, Giammartini E, Gentile M, et al. Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica. 2006;91(8): 1117-1120.
28. Goldin LR, Slager SL. Familial CLL: genes and environment. Hematology Am Soc Hematol Educ Program. 2007:339-345.
29. Houlston RS, Sellick G, Yuille M, et al. Causation of chronic lymphocytic leukemia - insights from familial disease. Leuk Res. 2003;27(10):871-876.
30. Goldin LR, Slager SL, Caporaso NE. Familial chronic lymphocytic leukemia. Curr Opin Hematol. 2010;17(4):350-355.
31. Fazi C, Dagklis A, Cottini F, et al. Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. Cytometry B Clin Cytom. 2010;78(suppl 1):S61-S68.
32. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol. 2008;26(27):4497-4503.
33. Klein U, Dalla-Favera R. New insights into the pathogenesis of chronic lymphocytic leukemia. Semin Cancer Biol. 2010;20(6):377-383.
34. Landgren O, Rapkin JS, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood. 2007;109(5):2198-2201.
35. Rossi D, Sozzi E, Puma A, et al. The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. Br J Haematol. 2009;146(1):64-75.
36. Fung SS, Hillier KL, Leger CS, et al. Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis. Leuk Lymphoma. 2007;48(6):1087-1091.
37. Xu W, Li JY, Wu YJ, et al. Clinical features and outcome of Chinese patients with monoclonal B-cell lymphocytosis. Leuk Res. 2009;33(12):1619-1622.
38. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009;360(7):659-667.
39. Lopez-Corral L, Gutierrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Research. 2011;17(7):1692-1700.
40. Shanafelt TD, Kay NE, Jenkins G, et al. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood. 2009;113(18):4188-4196.
41. Molica S, Mauro FR, Giannarelli D, et al. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica. 2011;96(2):277-283.
42. Shanafelt T, Kay NE, Rabe K, et al. Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age and sex matched general population. Presented at the 52nd ASH Annual Meeting and Exposition. December 4-7,2010, Orlando, FL. Blood (ASH Meeting Abstracts). 2010; 116(21):700. Abstract.
43. Lanasa MC, Allgood SD, Volkheimer AD, et al. Single-cell analysis reveals oligoclonality among 'low-count' monoclonal B-cell lymphocytosis. Leukemia. 2010;24(1):133-140.
44. Rawstron AC, Bennett F, Hillmen P, et al. The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia. Br J Haematol. 2007;139(5):724-729.
45. Bennett FL, Fenton JAL, O'Connor SJM, et al. Disease progression in monoclonal B-cell lymphocytosis is independent of VH mutation status. Presented at the 48th ASH Annual Meeting and Exposition. December 9-12,2006, Orlando, FL. Blood (ASH Meeting Abstracts). 2006;108(11):29. Abstract.
46. Kern W, Haferlach C, Dicker F, et al. Monoclonal B-Cell lymphocytosis (MBL) is closely related to chronic lymphocytic leukemia (CLL) and may be better classified as early-stage CLL. Presented at the 51st ASH Annual Meeting and Exposition. December 5-8,2009, New Orleans, LA. Blood (ASH Meeting Abstracts). 2009;114(22):2349. Abstract.
47. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
48. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997.
49. Faguet GB, Agee JF, Marti GE. Clone emergence and evolution in chronic lymphocytic leukemia: characterization of clinical, laboratory and immunophenotypic profiles of 25 patients. Leuk Lymphoma. 1992;6(4-5):345-356.
50. Bennett FL, Dalal S, Jack AS, et al. Five-year follow-up of monoclonal B-cell lymphocytosis (MBL) in individuals with a normal blood count: expansion of the abnormal B-cell compartment but no progressive disease. Presented at the 51st ASH Annual Meeting and Exposition. December 5-8,2009, New Orleans, LA. Blood (ASH Meeting Abstracts). 2009;114(22):59. Abstract.
51. Fagliano J, Berry M, Bove F, et al. Drinking water contamination and the incidence of leukemia: an ecologic study. Am J Public Health. 1990;80 (10):1209-1212.
52. Marwick C. Link found between Agent Orange and chronic lymphocytic leukaemia. BMJ. 2003;326(7383):242.
53. Glass DC, Gray CN, Jolley DJ, et al. Leukemia risk associated with low-level benzene exposure. Epidemiology. 2003;14(5):569-577.
54. Abramenko I, Bilous N, Chumak A, et al. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident - with focus on immunoglobulin heavy chain gene analysis. Leuk Res. 2008;32(4):535-545.
55. Rericha V, Kulich M, Rericha R, et al. Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: a case-cohort study. Environ Health Perspect. 2006;114(6):818-822.
56. Rawstron AC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program. 2009:430-439.
57. Hanson CA, Herrick JL, Morice WG, et al. Bone marrow involvement in monoclonal B-cell lymphocytosis (MBL). Eur Soc Hematol. 2008:1173. Abstract.
58. Rawstron AC, Hillmen P. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. Best Pract Res Clin Haematol. 2010;23(1):61-69.
59. Rawstron AC, Jones RA, Ferguson C, et al. Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. Br J Haematol. 2007;139(5):845-848.
60. Shanafelt TD, Kay NE. Comprehensive management of the CLL patient: a holistic approach. Hematology Am Soc Hematol Educ Program. 2007:324-331.
61. Cerhan JR, Wallace RB, Dick F, et al. Blood transfusions and risk of non-Hodgkin's lymphoma subtypes and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2001;10(4):361-368.
62. Castillo JJ, Dalia S, Pascual SK. Association between red blood cell transfusions and development of non-Hodgkin lymphoma: a meta-analysis of observational studies. Blood. 2010;116(16):2897-2907.
63. Pavletic SZ, Zhou G, Sobocinski K, et al. Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia. 2007;21(12): 2452-2455.
64. Herishanu Y, Eshel R, Kay S, et al. Unexpected detection of monoclonal B-cell lymphocytosis in a HLA-matched sibling donor on the day of allogeneic stem cell transplantation for a patient with chronic lymphocytic leukaemia: clinical outcome. Br J Haematol. 2010;149(6):905-907.
65. Hardy NM, Grady C, Pentz R, et al. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol. 2007;139(5):824-831.
66. Amato D, Oscier DG, Davis Z, et al. Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis. Am J Clin Pathol. 2007;128(2):333-338.
67. Wang C, Amato D, Rabah R, et al. Differentiation of monoclonal B lymphocytosis of undetermined significance (MLUS) and chronic lymphocytic leukemia (CLL) with weak CD5 expression from CD5(-) CLL. Leuk Res. 2002;26(12):1125-1129.
68. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-1213.
69. Eve HE, Furtado MV, Hamon MD, et al. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol. 2009;27(32):e189-e190; author reply e191.
70. Solal-Céligny P. Increasing treatment options in indolent non-Hodgkin's lymphoma. Semin Oncol. 2002;29(2 suppl 6):2-6.
71. Gribben JG. How I treat indolent lymphoma. Blood. 2007;109(11): 4617-4626.